Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study

. 2019 Jan 15 ; 326 () : 19-27. [epub] 20181107

Jazyk angličtina Země Nizozemsko Médium print-electronic

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid30447419
Odkazy

PubMed 30447419
DOI 10.1016/j.jneuroim.2018.11.002
PII: S0165-5728(18)30332-1
Knihovny.cz E-zdroje

Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.

CESP INSERM UMR 1018 Faculty of Medicine Paris Sud University Paris Saclay University UVSQ Villejuif France

CESP INSERM UMR 1018 Faculty of Medicine Paris Sud University Paris Saclay University UVSQ Villejuif France; Assistance Publique Hôpitaux de Paris Hôpital Paul Brousse Villejuif France

Clinic for Neurology 2 Kepler University Clinic Med Campus 3 Linz Austria

Danish Multiple Sclerosis Center Department of Neurology Rigshospitalet University of Copenhagen Copenhagen Denmark

Department of Clinical Neuroscience Karolinska Institutet Stockholm Sweden

Department of Clinical Neuroscience Karolinska Institutet Stockholm Sweden; KTH Royal Institute of Technology Stockholm Sweden

Department of Neurology Medical University of Graz Graz Austria

Department of Neurology Technische Universität München Munich Germany

Department of Neurology Technische Universität München Munich Germany; Munich Cluster for systems Neurology Munich Germany

Department of Neurology University Hospital Köln Köln Germany; University of Düsseldorf Medical Faculty Department of Neurology Düsseldorf Germany

Departments of Biomedicine and Neurology University Hospital Basel and University of Basel Basel Switzerland

Drug Metabolism Pharmacokinetics Biologics Novartis Institutes for Biomedical Research Basel Switzerland

GlaxoSmithKline R and D Uxbridge Middlesex United Kingdom

Hospital Regional Universitario de Málaga Instituto de investigación Biomédica de Málaga Universidad de Málaga Málaga Spain

Hospital Universitari Vall d'Hebron Centre d'Esclerosi Múltiple de Catalunya Barcelona Spain

Innsbruck Medical University Innsbruck Austria

INSERM UMR 996 Univ Paris Sud Faculty of Pharmacy Université Paris Saclay Châtenay Malabry France

Ipsen Biopharm Ltd Berkshire United Kingdom

Merck NBE Bioanalytics Ivrea Colleretto Giacosa Italy

MS Center Department of Neurology and Center Clinical Neuroscience Charles University Prague 1st Faculty of Medicine and General University Hospital Prague Czech Republic

Sanofi Aventis Germany Frankfurt Am Main Germany

SciCross AB Skövde Sweden

Università della Svizzera italiana Faculty of Biomedical Sciences Institute for Research in Biomedicine Bellinzona Switzerland

University of Düsseldorf Medical Faculty Department of Neurology Düsseldorf Germany

Citace poskytuje Crossref.org

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...